PROCEPT BioRobotics (PRCT) drew fresh attention after Evercore ISI initiated coverage, alongside two new Aquablation milestones: full enrollment in the WATER IV RP trial and FDA IDE approval for a second prostate cancer study.

At a share price of US$23.47, PROCEPT BioRobotics has seen a 7 day share price return of 12.57% following the Evercore ISI coverage and clinical milestones, but this sits against a 1 year total shareholder return that declined 59.66%, pointing to short term momentum alongside a weaker longer term record.

If this kind of move in PROCEPT BioRobotics has your attention, it may be a good moment to broaden your radar with other robotics and automation opportunities through the Simply Wall St screener for 29 robotics and automation stocks.

With PROCEPT BioRobotics now trading at US$23.47 against an analyst price target of US$30.20 and a value score of 1, the key question is whether the recent rebound signals a mispriced opportunity or whether the market already anticipates future growth.

Most Popular Narrative: 7.1% Undervalued

Against PROCEPT BioRobotics' last close at $23.47, the most followed narrative on Simply Wall St marks out a fair value of $25.26, implying a modest discount that some investors are watching closely.

I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense. The sell side analyst who chased the share price up to highs in 2024 (when the price was way too frothy) are doing the same thing now by revising the share price lower and lower, when clearly the company is still doing a great job. The recent downgrade by Leerink, citing PAE as a possible headwind for PRCT growth, is in direct opposition to what Larry Wood (CEO) stated at the last earnings call. To quote Larry Wood, “I don’t think PAE is a headwind for us at all. I think PAE is a big red herring. It’s a procedure that really does not get performed in any volume in Europe. And the reason it doesn’t get performed is because it doesn’t get paid for because it’s not a very good procedure.” So if you believe Larry Wood, then the company has been grossly oversold and looks very very cheap down here. If PRCT hit the Q2 numbers watch all the sheep suddenly revise their target prices back up again. I think fair value is still up at $47. PRCT had a reassessment of how to report handpiece sales versus procedures and therefore there was a shortfall on revenue. Clearly they could have stuck with the old model and revenue would have been better. Larry is doing a great job of making reporting a direct reflection of procedures being done. If the numbers are delivered, watch this thing fly.

Curious what sits behind that $25.26 fair value for PROCEPT BioRobotics? The narrative leans on double digit revenue growth, a future profit margin shift and a valuation multiple that assumes a very different earnings profile to today. The interesting part is how those three levers work together, not alone.

Result: Fair Value of $25.26 (UNDERVALUED)

However, PROCEPT BioRobotics still carries risks, including its current loss of $102.473 million and its reliance on continued revenue growth of 17.71% to support the thesis.

Next Steps

If the mixed sentiment around PROCEPT BioRobotics leaves you unsure, take a closer look at both sides of the story and act quickly to form your own view with 1 key reward and 1 important warning sign

Looking for more investment ideas beyond PROCEPT BioRobotics?

If PROCEPT BioRobotics has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not late to the next move.

• Target potential bargain opportunities by scanning companies trading below their estimated worth with the 41 high quality undervalued stocks.
• Prioritize resilience by focusing on companies that pair sturdy finances with low overall risk using the 73 resilient stocks with low risk scores.
• Spot overlooked opportunities before they hit the mainstream by reviewing the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.